Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
30232144
DOI
10.1158/1535-7163.mct-18-0696
PII: 1535-7163.MCT-18-0696
Knihovny.cz E-resources
- MeSH
- Arginine pharmacology MeSH
- Nitric Oxide Donors pharmacology MeSH
- Doxorubicin analogs & derivatives pharmacology MeSH
- Hydroxyurea pharmacology MeSH
- Macromolecular Substances pharmacology MeSH
- Disease Models, Animal MeSH
- Mice MeSH
- Neoplasms blood supply pathology MeSH
- Nanoparticles chemistry MeSH
- Nanomedicine * MeSH
- Nitroglycerin pharmacology MeSH
- Nitric Oxide biosynthesis MeSH
- Permeability MeSH
- Rats, Sprague-Dawley MeSH
- Antineoplastic Agents pharmacology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Arginine MeSH
- Nitric Oxide Donors MeSH
- Doxorubicin MeSH
- Hydroxyurea MeSH
- Macromolecular Substances MeSH
- Nitroglycerin MeSH
- Nitric Oxide MeSH
- pirarubicin MeSH Browser
- Antineoplastic Agents MeSH
Enhanced permeability and retention (EPR) effect-based nanomedicine is a promising strategy for successful anticancer therapy. The EPR effect is based on tumor blood flow. Because advanced large tumors, as frequently seen in clinical settings, are heterogeneous, with regions of defective vasculature and blood flow, achieving the desired tumor drug delivery is difficult. Here, we utilized the EPR effect to increase drug delivery. To augment the EPR effect for improved therapeutic effects of nanomedicine, we exploited vascular mediators-the nitric oxide (NO) generators nitroglycerin (NG), hydroxyurea, and l-arginine. These compounds generate NO in tumors with relatively high selectivity. Using different nanosized drugs in our protocol significantly increased (1.5-2 times) delivery of nanomedicines to different solid tumor models, along with markedly improving (2-3-fold) the antitumor effects of these drugs. Also, in 7,12-dimethylbenz[a]anthracene-induced advanced end-stage breast cancer, often seen in clinical settings, 2 mg/kg polymer-conjugated pirarubicin (P-THP) with NG (0.2 mg/mouse) showed better effects than did 5 mg/kg P-THP, and 5 mg/kg P-THP used with NG resulted in cures or stable tumors (no tumor growth) for up to 120 days. Moreover, in a murine autochthonous azoxymethane/dextran sulfate sodium-induced colon cancer model, NO donors markedly improved the therapeutic effects of P-THP even after just one injection, results that were comparable with those achieved with three weekly P-THP treatments. These findings strongly suggest the potential usefulness of NO donors as EPR effect enhancers to improve the therapeutic efficacy of nanomedicines.
BioDynamics Research Foundation Kumamoto Japan
Department of Microbiology Graduate School of Medical Sciences Kumamoto University Kumamoto Japan
Faculty of Pharmaceutical Sciences Sojo University Kumamoto Japan
Institute of Macromolecular Chemistry Czech Academy of Sciences Prague Czech Republic
References provided by Crossref.org
HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery